Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02

Journal of Clinical Oncology

Volumn 24, Issue 13, 2006, Pages 2098-2104

  Rischin, Danny ^a   Hicks, Rodney J ^a   Fisher, Richard ^a   Binns, David ^a   Corry, June ^a   Porceddu, Sandro ^a   Peters, Lester J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CISPLATIN; FLUOROURACIL; TIRAPAZAMINE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; MISONIDAZOLE; TRIAZINE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; CELL HYPOXIA; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; SCINTISCANNING;

CELL HYPOXIA; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT FAILURE; TRIAZINES;

EID: 33646454133     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.2878     Document Type: Article

References (35)

1. Gray LH, Conger AD, Ebert M, et al: Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648, 1953
2. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
3. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39, 1996
4. Corry J, Rischin D: Strategies to overcome accelerated repopulation and hypoxia: What have we learned from clinical trials? Semin Oncol 31:802-808, 2004
5. Dorie MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993
6. Dorie MJ, Menke D, Brown JM: Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys 28:145-150, 1994
7. Brown JM, Lemmon MJ: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50:7745-7749, 1990
8. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
9. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
10. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
11. Rischin D, Peters L, Hicks R, et al: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19:535-542, 2001
12. Rischin D, Peters L, Fisher R, et al: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87, 2005
13. Corry J, Rischin D, Smith JG, et al: Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer. Radiother Oncol 54:123-127, 2000
14. Garden AS, Glisson BS, Ang KK, et al: Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: Toxicities and responses. J Clin Oncol 17:2390-2395, 1999
15. Garden AS, Harris J, Vokes EE, et al: Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22:2856-2864, 2004
16. Benard F, Smith RJ, Hustinx R, et al: Clinical evaluation of processing techniques for attenuation correction with 137Cs in whole-body PET imaging. J Nucl Med 40:1257-1263, 1999
17. Hicks RJ, Rischin D, Fisher R, et al: Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32:1384-1391, 2005
18. Zeman EM, Brown JM, Lemmon MJ, et al: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1986
19. Senan S, Rampling R, Graham MA, et al: Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3:31-38, 1997
20. Von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group - Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18:1351-1359, 2000
21. Le QT, Kovacs MS, Dorie MJ, et al: Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 56:375-383, 2003
22. Gatenby RA, Kessler HB, Rosenblum JS, et al: Oxygen distribution in squamous cell carcinomametastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
23. Rudat V, Stadler P, Becker A, et al: Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 177:462-468, 2001
24. Stadler P, Becker A, Feidmann HJ, et al: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44:749-754, 1999
25. Vanselow B, Eble MJ, Rudat V, et al: Oxygenation of advanced head and neck cancer: Prognostic marker for the response to primary radiochemotherapy. Otolaryngol Head Neck Surg 122:856-862, 2000
26. Brown JM, Le QT: Tumor hypoxia is important in radiotherapy, but how should we measure it? Int J Radiat Oncol Biol Phys 54:1299-1301, 2002
27. Evans SM, Koch CJ: Prognostic significance of tumor oxygenation in humans. Cancer Lett 195: 1-16, 2003
28. Becker A, Hansgen G, Bloching M, et al: Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 42:35-41, 1998
29. Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia-inducible factor-1 alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911-2916, 2001
30. Janssen HL, Haustermans KM, Sprong D, et al: HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 54:1537-1549, 2002
31. Kaanders JH, Wijffels KI, Marres HA, et al: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066-7074, 2002
32. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202, 2002
33. Koukourakis MI, Giatromanolaki A, Sivridis E. et al: Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399-3403, 2001
34. Le QT, Sutphin PD, Raychaudhuri S, et al: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67, 2003
35. Overgaard J, Eriksen JG, Nordsmark M, et al: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764, 2005